Using new genomic technology, Garcia and his colleagues for the first time identified an enzyme called extracellular Nicotinamide phosphoribosyltransferase or eNAMPT, as a important factor in ...

Alphina Therapeutics Inc. has described nicotinamide phosphoribosyltransferase (NAmPRTase; Nampt) inhibitors reported to be useful for the treatment of cancer, and autoimmune, inflammatory and ...

ABSTRACT: In North Carolina, candida infections are on the rise and pose a significant threat to human health in clinical settings. In addition, the rise of resistance to antifungal drugs has only ...

Edited by Susan G. Amara, University of Pittsburgh School of Medicine, Pittsburgh, PA, and approved January 19, 2012 (received for review November 3, 2011) Our present study on the effect of HPRT ...

The Nicotinamide Phosphoribosyltransferase pipeline drugs market research report outlays comprehensive information on the Nicotinamide Phosphoribosyltransferase targeted therapeutics, complete with ...

aDepartment of Pathology, The University of Arizona Health Sciences, United States bDepartment of Medicine, The University of Arizona Health Sciences, United States cDepartment of Radiation Oncology, ...

A wide range of cellular assays were performed to assess cell death, mitochondrial function, knockdown of nicotinate phosphoribosyltransferase gene, G-protein coupled receptor agonism, and ...

The condition occurs due to issues with the enzyme known as hypoxanthine-guanine phosphoribosyltransferase (HPRT), which results in the accumulation of uric acid. Lesch-Nyhan syndrome is an X ...

A typical scenario is the drug screening task, i.e., the inhibitory potency prediction of the nicotinamide phosphoribosyltransferase inhibitors. Extensive experiments on nine real-world datasets (four ...

Nicotinamide phosphoribosyltransferase (NAMPT) is the pharmacologically targetable rate-limiting enzyme in this pathway. We report on the effect of targeting NAMPT in models of pediatric ...